Home

In-person & virtual event - Lacutamab: a Phase 3-ready asset

Monalizumab (anti-NKG2A antibody), partnered with AstraZeneca

IPH4502, our Antibody Drug Conjugate targeting Nectin-4

Third quarter 2025 Financial Results and Business Updates | November 13, 2025

Lacutamab, a first-in-class antibody for cutaneous t-cell lymphoma

Collaborating with a strong network to advance our pipeline